Monthly Archives: August 2017
Alcohol Use and Cardiovascular Disease Risk in Patients with Nonalcoholic Fatty Liver Disease
Cardiovascular disease (CVD) is the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD). Moderate drinking (vs abstinence) is associated with lower risk of CVD in the general population. We assessed whether alcohol use … Continue reading
Metabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues
Effective treatments are needed for hepatic steatosis characterized by accumulation of triglycerides in hepatocytes, which leads to hepatocellular carcinoma. MicroRNA 122 (MIR122) is expressed only in the liver, where it regulates lipid metabolism. We … Continue reading
Interactions Between Platelets and Inflammatory Monocytes Affect Sickness Behavior in Mice With Liver Inflammation
Patients with inflammatory liver disease commonly develop debilitating symptoms, called sickness behaviors, which arise via changes in brain function. Monocytes that produce tumor necrosis factor (TNF) interact with cerebral endothelial cells to activa… Continue reading
The Irony of Long-term Acid Suppression
The effect of acid suppression on decreasing non-heme intestinal iron absorption has been known for decades.1 The clinical implications of this effect in the population, however, has not been great because human intestinal iron absorption is dominated … Continue reading
The irony of long term acid suppression
Exam 4: American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Does the Use of Doppler Endoscopic Probe in Hemostasis of Nonvariceal Gastrointestinal Bleeding Increase Efficacy or Work Load?
I read with interest the article by Jensen et al1 regarding the use of a Doppler endoscopic probe (DEP) in hemostasis of nonvariceal gastrointestinal bleeding. The authors demonstrated that use of a DEP can significantly reduce the rebleeding rate of … Continue reading
Management of Gastroesophageal Reflux Disease
Management of GERD commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for patients without alarm symptoms. Optimization of therapy (improving compliance and timing of PPI doses), or increa… Continue reading